Rheumatoid and Inflammatory Arthritis

You have full text access to this OnlineOpen article

Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients†‡

  1. Rogier M. Thurlings1,
  2. Marie Boumans1,
  3. Janneke Tekstra2,
  4. Joel A. van Roon2,
  5. Koen Vos3,
  6. Daisy Marie van Westing1,
  7. Lisa G. van Baarsen1,
  8. Carina Bos4,
  9. Kyriakos A. Kirou5,
  10. Danielle M. Gerlag1,
  11. Mary K. Crow5,§,
  12. Johannes W. Bijlsma2,
  13. Cornelis L. Verweij4,¶,
  14. Paul P. Tak1,‖,*

Article first published online: 30 NOV 2010

DOI: 10.1002/art.27702

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 62, Issue 12, pages 3607–3614, December 2010

Additional Information

How to Cite

Thurlings, R. M., Boumans, M., Tekstra, J., van Roon, J. A., Vos, K., van Westing, D. M., van Baarsen, L. G., Bos, C., Kirou, K. A., Gerlag, D. M., Crow, M. K., Bijlsma, J. W., Verweij, C. L. and Tak, P. P. (2010), Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients. Arthritis & Rheumatism, 62: 3607–3614. doi: 10.1002/art.27702

Author Information

  1. 1

    Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

  2. 2

    University Medical Centre Utrecht, Utrecht, The Netherlands

  3. 3

    Academic Medical Center, University of Amsterdam, and Jan van Breemen Institute, Amsterdam, The Netherlands

  4. 4

    VU University Medical Center, Amsterdam, The Netherlands

  5. 5

    Hospital for Special Surgery, New York, New York

  1. §

    Dr. Crow has received consulting fees, speaking fees, and/or honoraria from Biogen Idec, Bristol-Myers Squibb, Genentech, Roche, Idera, MedImmune, and Novo Nordisk (less than $10,000 each) and has filed a patent application for an interferon assay.

  2. Dr. Verweij has filed a patent application for a method of predicting responsiveness to rituximab.

  3. ‖

    Dr. Tak has received consulting fees from Roche (less than $10,000).

*Division of Clinical Immunology and Rheumatology, F4-105, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands

  1. †

    ISRCTN: 05568900.

  2. ‡

    This publication reflects only the authors' views. The European Community is not liable for any use that may be made of the information herein.

  3. §

    Dr. Crow has received consulting fees, speaking fees, and/or honoraria from Biogen Idec, Bristol-Myers Squibb, Genentech, Roche, Idera, MedImmune, and Novo Nordisk (less than $10,000 each) and has filed a patent application for an interferon assay.

  4. Dr. Verweij has filed a patent application for a method of predicting responsiveness to rituximab.

  5. ‖

    Dr. Tak has received consulting fees from Roche (less than $10,000).

Publication History

  1. Issue published online: 30 NOV 2010
  2. Article first published online: 30 NOV 2010
  3. Accepted manuscript online: 18 AUG 2010 02:39PM EST
  4. Manuscript Accepted: 5 AUG 2010
  5. Manuscript Received: 9 MAR 2010

Funded by

  • European Community Sixth Framework Programme (project AutoCure)
  • The Netherlands Genomics Initiative (IOP Genomics) from The Netherlands Organization for Scientific Research
  • Dutch Arthritis Association (Reumafonds)

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (202K)

REFERENCES

  • 1
    Burdick LM, Somani N, Somani AK. Type I IFNs and their role in the development of autoimmune diseases. Expert Opin Drug Saf 2009; 8: 459–72.
  • 2
    Crow MK. Type I interferon in systemic lupus erythematosus. Curr Top Microbiol Immunol 2007; 316: 359–86.
  • 3
    Van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, Voskuyl AE, Rustenburg F, Baggen JM, et al. Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann Rheum Dis 2007; 66: 1008–14.
  • 4
    Bos CL, van Baarsen LG, Timmer TC, Overbeek MJ, Basoski NM, Rustenburg F, et al. Molecular subtypes of systemic sclerosis in association with anticentromere antibodies and digital ulcers. Genes Immun 2009; 10: 210–8.
  • 5
    Bilgic H, Ytterberg SR, Amin S, McNallan KT, Wilson JC, Koeuth T, et al. Interleukin-6 and type I interferon–regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum 2009; 60: 3436–46.
    Direct Link:
  • 6
    Van Baarsen LG, Vosslamber S, Tijssen M, Baggen JM, van der Voort LF, Killestein J, et al. Pharmacogenomics of interferon-β therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients. PLoS One 2008; 3: e1927.
  • 7
    Emamian ES, Leon JM, Lessard CJ, Grandits M, Baechler EC, Gaffney PM, et al. Peripheral blood gene expression profiling in Sjögren's syndrome. Genes Immun 2009; 10: 285–296.
  • 8
    Leandro MJ, De la Torre I. Translational Mini-Review Series on B Cell-Directed Therapies: the pathogenic role of B cells in autoantibody-associated autoimmune diseases—lessons from B cell-depletion therapy. Clin Exp Immunol 2009; 157: 191–7.
    Direct Link:
  • 9
    Dorner T, Kinnman N, Tak PP. Targeting B cells in immune mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers. Pharmacol Ther 2010; 125: 464–75.
  • 10
    Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al, for the DANCER Study Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006; 54: 1390–400.
    Direct Link:
  • 11
    Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al, for the REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54: 2793–806.
    Direct Link:
  • 12
    Teng YK, Tekstra J, Breedveld FC, Lafeber F, Bijlsma JW, van Laar JM. Rituximab fixed retreatment versus on-demand retreatment in refractory rheumatoid arthritis: comparison of two B cell depleting treatment strategies. Ann Rheum Dis 2009; 68: 1075–7.
  • 13
    Thurlings RM, Vos K, Wijbrandts CA, Zwinderman AH, Gerlag DM, Tak PP. Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann Rheum Dis 2008; 67: 917–25.
  • 14
    Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight–joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44–8.
    Direct Link:
  • 15
    Hua J, Kirou K, Lee C, Crow MK. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti–RNA binding protein autoantibodies. Arthritis Rheum 2006; 54: 1906–16.
    Direct Link:
  • 16
    Niewold TB, Hua J, Lehman TJ, Harley JB, Crow MK. High serum IFN-α activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun 2007; 8: 492–502.
  • 17
    Baccala R, Kono DH, Theofilopoulos AN. Interferons as pathogenic effectors in autoimmunity. Immunol Rev 2005; 204: 9–26.
    Direct Link:
  • 18
    Raychaudhuri S. Recent advances in the genetics of rheumatoid arthritis. Curr Opin Rheumatol 2010; 22: 109–18.
  • 19
    Sigurdsson S, Padyukov L, Kurreeman FA, Liljedahl U, Wiman AC, Alfredsson L, et al. Association of a haplotype in the promoter region of the interferon regulatory factor 5 gene with rheumatoid arthritis. Arthritis Rheum 2007; 56: 2202–10.
    Direct Link:
  • 20
    Stahl EA, Raychaudhuri S, Remmers EF, Xie G, Eyre S, Thomson BP, et al. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet 2010; 42: 508–14.
  • 21
    Bave U, Nordmark G, Lovgren T, Ronnelid J, Cajander S, Eloranta ML, et al. Activation of the type I interferon system in primary Sjögren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum 2005; 52: 1185–95.
    Direct Link:
  • 22
    Baccala R, Hoebe K, Kono DH, Beutler B, Theofilopoulos AN. TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat Med 2007; 13: 543–51.
  • 23
    Kelly KM, Zhuang H, Nacionales DC, Scumpia PO, Lyons R, Akaogi J, et al. “Endogenous adjuvant” activity of the RNA components of lupus autoantigens Sm/RNP and Ro 60. Arthritis Rheum 2006; 54: 1557–67.
    Direct Link:
  • 24
    Kariuki SN, Moore JG, Kirou KA, Crow MK, Utset TO, Niewold TB. Age- and gender-specific modulation of serum osteopontin and interferon-α by osteopontin genotype in systemic lupus erythematosus. Genes Immun 2009; 10: 487–94.
  • 25
    Sweeney SE, Mo L, Firestein GS. Antiviral gene expression in rheumatoid arthritis: role of IKKε and interferon regulatory factor 3. Arthritis Rheum 2007; 56: 743–52.
    Direct Link:
  • 26
    Theofilopoulos AN, Baccala R, Beutler B, Kono DH. Type I interferons (α/β) in immunity and autoimmunity. Annu Rev Immunol 2005; 23: 307–36.
  • 27
    Kariuki SN, Kirou KA, MacDermott EJ, Barillas-Arias L, Crow MK, Niewold TB. Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-α in lupus patients in vivo. J Immunol 2009; 182: 34–8.
  • 28
    Tak PP. IFN-β in rheumatoid arthritis. Front Biosci 2004; 1: 3242–7.
  • 29
    Vervoordeldonk MJ, Aalbers CJ, Tak PP. Interferon β for rheumatoid arthritis: new clothes for an old kid on the block. Ann Rheum Dis 2009; 68: 157–8.
  • 30
    Van Baarsen LG, Bos WH, Rustenburg F, van der Pouw Kraan TC, Wolbink GJ, Dijkmans BA, et al. Gene expression profiling in autoantibody-positive patients with arthralgia predicts development of arthritis. Arthritis Rheum 2010; 62: 694–704.
    Direct Link:
  • 31
    Cantaert T, van Baarsen LG, Wijbrandts CA, Thurlings RM, van de Sande MG, Bos C, et al. Type I interferons have no major influence on humoral autoimmunity in rheumatoid arthritis. Rheumatology (Oxford) 2010; 49: 156–66.
  • 32
    Van Baarsen LG, Wijbrandts CA, Rustenburg F, Cantaert T, van der Pouw Kraan TC, Baeten DL, et al. Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment. Arthritis Res Ther 2010; 12: R11.
  • 33
    Mavragani CP, La DT, Stohl W, Crow MK. Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-β/α ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohort. Arthritis Rheum 2010; 62: 392–401.
    Direct Link:
  • 34
    Van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, Rustenburg F, Baggen JM, Verweij CL, et al. Responsiveness to anti-tumour necrosis factor α therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients. Ann Rheum Dis 2008; 67: 563–6.
  • 35
    Wijbrandts CA, Dijkgraaf MG, Kraan MC, Vinkenoog M, Smeets TJ, Dinant H, et al. The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor α expression in the synovium. Ann Rheum Dis 2008; 67: 1139–44.
  • 36
    Dass S, Rawstron AC, Vital EM, Henshaw K, McGonagle D, Emery P. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum 2008; 58: 2993–9.
    Direct Link:
  • 37
    Tekstra J, Groot Kormelink T, Thurlings RM, Boumans MJ, Vos K, Tak PP, et al. Inhibition of immunoglobulin light chains by rituximab correlates with inhibition of clinical activity in patients with RA [abstract]. Arthritis Rheum 2009; 60 Suppl: S255.
  • 38
    Cioc AM, Vanderwerf SM, Peterson BA, Robu VG, Forster CL, Pambuccian SE. Rituximab-induced changes in hematolymphoid tissues found at autopsy. Am J Clin Pathol 2008; 130: 604–12.
  • 39
    Li J, Proulx ST, Zhou Q, Kuzin I, Dunn R, Looney RJ, et al. Effective anti-CD20 therapy for arthritis is associated with increased lymphatic flow and B-cell depletion in lymph nodes [abstract]. Arthritis Rheum 2009; 60 Suppl: S452–3.
  • 40
    Nakou M, Katsikas G, Sidiropoulos P, Bertsias G, Papadimitraki E, Raptopoulou A, et al. Rituximab therapy reduces activated B cells both in the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response. Arthritis Res Ther 2009; 11: R131.
  • 41
    Rehnberg M, Amu S, Tarkowski A, Bokarewa MI, Brisslert M. Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis. Arthritis Res Ther 2009; 11: R123.
  • 42
    Boumans MJ, Tak PP. Rituximab treatment in rheumatoid arthritis: how does it work? Arthritis Res Ther 2009; 11: 134.
  • 43
    Radbruch A, Muehlinghaus G, Luger EO, Inamine A, Smith KG, Dorner T, et al. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol 2006; 6: 741–50.
  • 44
    Looney RJ. B cell-targeted therapies for systemic lupus erythematosus: an update on clinical trial data. Drugs 2010; 26; 70: 529–40.
View Full Article (HTML) Get PDF (202K)